CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric NeuroblastomaZhi-Yong Zhong*, Bao-Jun Shi, Hui Zhou and Wen-Bo Wang
Department of Pediatric Surgery, The Second of Hospital of Hebei Medical University, PRChina
- Corresponding Author:
- Dr. Zhi-Yong Zhong
Pediatric Surgery Department
The Second Hospital of Hebei Medical University
215 Heping West Road, Shijiazhuang, PR China
Tel: +86 132 4122 2181
E-mail: [email protected]
Received Date: July 28, 2017; Accepted Date: July 29, 2017; Published Date: July 31, 2017
Citation: Zhong ZY, Shi BJ, Zhou H, Wang WB (2017) CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric Neuroblastoma. J Stem Cell Res Ther 7:394. doi: 10.4172/2157-7633.1000394
Copyright: © 2017 Zhong ZY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN gene exists in nearly half of the NB patient and its association with rapid disease progression and poor outcome is controversial. Cancer Stem Cells (CSCs) characterization in NB has been rarely studied. This study is to figure out whether the MYCN gene and CSCs are associated with chemotherapy resistance and survival time in the NB patients.
Methods: Based on unequivocal pathological diagnosis, 50 NB patients are recruited. MYSN amplification is measured before any therapy. The CSCs are derived and their multi-potencies are tested by directed differentiation. Response to chemotherapy and average survival time of these patients are gathered and compared with following groups: CD133+, CD133-, MYCN ≥ 5, MYCN<5, CD133+ plus MYCN ≥ 5, CD133- plus MYCN<5.
Results: CD133+ CSCs differentiate into neuron like cells; CD133+ patients have significant poorer response to chemotherapy comparing with the CD133- patients (P<0.01); CD133+ and MYCN ≥ 5 patients have significantly shorter average survival time than the CD133- and MYCN<5 patients (P<0.01).
Conclusions: CD133+ CSCs produce chemo-resistance. CD133 and MYCN amplification can be used together as a prognostic value for predicting disease outcome.